Search research articles
Contact Us
Filters
Showing results (221-230 of 361) with videos related to
Page
of 37
Sort By:
Blood
|
March 11, 2006
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis
Maaike de Fost, Carla E M Hollak, Johanna E M Groener, et al.
Chemical Science
|
September 1, 2023
Fluorescence polarisation activity-based protein profiling for the identification of deoxynojirimycin-type inhibitors selective for lysosomal retaining alpha- and beta-glucosidases
Daniël van der Gracht, Rhianna J Rowland, Véronique Roig-Zamboni, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 6, 2011
Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease
L van Dussen, P Lips, V E Everts, et al.
Journal of Inherited Metabolic Disease
|
January 9, 2007
The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels
A C Vedder, G E Linthorst, M J van Breemen, et al.
Blood
|
April 12, 2012
Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis
Sarah M Lo, Murim Choi, Jun Liu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer
J H R J Degens, K J C Sanders, E E C de Jong, et al.
Journal of Neuroendocrinology
|
March 4, 2025
Critical role of arcuate nucleus kisspeptin and Kiss1R in regulation of the ovine luteinizing hormone surge
Max J Griesgraber, Lique M Coolen, Kayla M Onslow, et al.
Journal of Inherited Metabolic Disease
|
October 27, 2004
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease
D Elstein, C Hollak, J M F G Aerts, et al.
Ebiomedicine
|
December 1, 2018
The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
Cathrine K Fog, Paola Zago, Erika Malini, et al.
Plos One
|
January 16, 2016
Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease
André R A Marques, Tanit L Gabriel, Jan Aten, et al.
Page
of 37
Search research articles
Search
Showing results (221-230 of 361) with videos related to
Sort By:
Page
of 37
Blood
|
March 11, 2006
Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis
Maaike de Fost, Carla E M Hollak, Johanna E M Groener, et al.
Chemical Science
|
September 1, 2023
Fluorescence polarisation activity-based protein profiling for the identification of deoxynojirimycin-type inhibitors selective for lysosomal retaining alpha- and beta-glucosidases
Daniël van der Gracht, Rhianna J Rowland, Véronique Roig-Zamboni, et al.
The Journal of Clinical Endocrinology and Metabolism
|
May 6, 2011
Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease
L van Dussen, P Lips, V E Everts, et al.
Journal of Inherited Metabolic Disease
|
January 9, 2007
The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels
A C Vedder, G E Linthorst, M J van Breemen, et al.
Blood
|
April 12, 2012
Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis
Sarah M Lo, Murim Choi, Jun Liu, et al.
Lung Cancer (Amsterdam, Netherlands)
|
June 16, 2019
The prognostic value of early onset, CT derived loss of muscle and adipose tissue during chemotherapy in metastatic non-small cell lung cancer
J H R J Degens, K J C Sanders, E E C de Jong, et al.
Journal of Neuroendocrinology
|
March 4, 2025
Critical role of arcuate nucleus kisspeptin and Kiss1R in regulation of the ovine luteinizing hormone surge
Max J Griesgraber, Lique M Coolen, Kayla M Onslow, et al.
Journal of Inherited Metabolic Disease
|
October 27, 2004
Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease
D Elstein, C Hollak, J M F G Aerts, et al.
Ebiomedicine
|
December 1, 2018
The heat shock protein amplifier arimoclomol improves refolding, maturation and lysosomal activity of glucocerebrosidase
Cathrine K Fog, Paola Zago, Erika Malini, et al.
Plos One
|
January 16, 2016
Gpnmb Is a Potential Marker for the Visceral Pathology in Niemann-Pick Type C Disease
André R A Marques, Tanit L Gabriel, Jan Aten, et al.
Page
of 37